Overview
Registration
Faculty
Agenda
View Archive

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Puma Biotechnology, Inc.

Navigating Treatment Options for HER2+ Breast Cancer Across the Disease Continuum: An Expert Tumor Board Discussion

Navigating Treatment Options for HER2+ Breast Cancer Across the Disease Continuum: An Expert Tumor Board Discussion


Wednesday, December 9, 2020

7:30 PM – 9:30 PM CST

Live, Interactive Virtual Webcast!

Overview

For patients with HER2+ breast cancer, treatment with HER2-targeted therapies has been shown to improve both short-term and long-term survival, in both early-stage and advanced/metastatic disease. Over the past few years, results from pivotal trials and new regulatory approvals have expanded treatment options, and treatment paradigms are rapidly evolving, in both (neo)adjuvant and metastatic settings. In addition, there are several promising new HER2-targeted agents in late-phase clinical trials, which provide further options for patients with relapsed/refractory disease.

Navigating Treatment Options for HER2+ Breast Cancer Across the Disease Continuum: An Expert Tumor Board Discussion will highlight the clinical evidence supporting current treatment options along with expert discussion regarding how to integrate and apply these data to optimize patient outcomes. The activity will include a series of case presentations to illuminate treatment decisions related to selecting adjuvant therapy for patients with early-stage HER2+ breast cancer, and sequencing lines of treatment for patients with HER2+ metastatic breast cancer based on patient and disease characteristics. This program is designed to be interactive through a combination of didactic presentations, challenging case studies, panel discussions, and a question-and-answer session to allow you the opportunity to hear from experts in the field of breast cancer concerning the challenges you face regularly in the clinic.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Puma Biotechnology, Inc.

Target Audience

This educational program is directed toward medical oncologists. Surgical oncologists, pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the management and treatment of breast cancer are also invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Incorporate emerging clinical evidence with HER2-targeted agents into individualized treatment plans for patients with early-stage or advanced/metastatic HER2+ breast cancer
  • Review current treatment standards and emerging options for patients with HER2+ breast cancer brain metastases
  • Consider ongoing clinical trials of investigational agents for HER2+ breast cancer, and the potential effect of emerging data on current treatment algorithms
  • Implement effective strategies to prevent or manage treatment-related adverse events in patients receiving HER2-targeted therapy for breast cancer

Benefits of Attending:

  • Review clinical evidence supporting specific treatment options for HER2+ breast cancer
  • Hear expert perspectives on how to integrate recently approved HER2-targeted therapies into current treatment paradigms
  • Gain insights into applying the latest data to real-world patient scenarios
  • Learn best practices for managing adverse events associated with HER2-targeted therapies

Hot Topics:

  • Expanded adjuvant treatment options for high-risk HER2+ early-stage breast cancer
  • Integrating new HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors into the treatment algorithm for HER2+ MBC
  • New paradigms for managing HER2+ brain metastases

Program Chair

Joyce O'Shaughnessy, MD
Joyce O'Shaughnessy, MD
Celebrating Woman Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
Chair, Breast Cancer Research Program
The US Oncology Network
Dallas, TX

Registration

2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
 
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

Meeting information is accurate at the time of posting.



Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By